ArticleClinical and molecular hepatology2026

Key challenges in cost-effectiveness analyses of emerging MASLD therapies: adherence, adverse events, cardiometabolic benefits, and age-related uncertainty: Correspondence to editorial on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".

Eileen L Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.